28 Mar 2016
Cadila Healthcare Limited has entered into a definitive agreement to acquire ‘Actibile’ from Albert David Limited (ADL). The brand falls in the gastroenterology segment and is used for dissolving gall bladder stones. The deal will be financed through internal accruals
The gastrointestinal segment has been one of our core focus segment of Zydus. This acquisition will strengthen Zydus Gastro portfolio of brands and leverage our equity in gastro segment.
Actibile contains Ursodeoxycholic Acid
Ursodiol, also known as ursodeoxycholic acid and the abbreviation UDCA, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria.